Search results
Results from the WOW.Com Content Network
By the end of December 2021, 758,891 doses had been administered and 583,609 persons (25% of the targeted population) were fully vaccinated. By the end of March 2022, 818,931 doses had been administered and 640,464 persons were fully vaccinated. By the end of April 2022, 831,318 doses had been administered and 652,422 persons were fully vaccinated.
COVAX began distributing vaccines in February 2021. Though COVAX promised 100 million doses by the end of March, [3] [4] this goal was not reached until 6 July. [5] By mid-August 2021, COVAX delivered 200 million vaccine doses to nearly 140 countries instead of the 600 million doses initially projected.
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi ...
COVAX sought to fundraise US$6.8 billion to purchase and deliver vaccines to participating countries in proportion to their populations. [32] On 18 December 2020, the facility announced agreements with vaccine manufacturers to supply 1.3 billion doses for 92 low-middle income countries in the first half of 2021.
On 24 February 2021, a shipment of 600,000 Oxford–AstraZeneca COVID-19 vaccine to Accra via COVAX made it the first country in Africa to receive vaccines via the initiative. [5] The vaccination campaign began on 1 March 2021 as president Akufo-Addo received the first jab.
As of 21 February 2022, India had delivered around 16.29 crore (162.9 million) doses of vaccines to 96 countries. [3] Of these, 1.43 crore (14.3 million) doses were gifted to 98 countries by the Government of India. The remaining 10.71 crore were supplied by the vaccine producers under its commercial and 4.15 crore were supplied by COVAX ...
Phases 2 and 3 clinical trials of COVAX-19 are being conducted in Iran under a co-operation agreement. [8] Phase 2 clinical trials started in May 2021 and Phase 3 trials commenced in August 2021. In the phase 2 trials, 400 Iranian volunteers were injected with either a placebo or the first dose of the vaccine.
The firm, in collaboration with the Government of Odisha, is establishing another facility at Odisha Biotech Park in Bhubaneswar to commence Covaxin production by June 2022. [ 14 ] [ 15 ] In December 2020, Ocugen entered into a partnership with Bharat Biotech to co-develop and exclusively commercialise Covaxin in the US market; [ 16 ] [ 17 ] in ...